History

Boston Biomedical: History and Achievements

Boston Biomedical was founded in 2006, and for the past 12 years our researchers have established the company as a leader in the field of therapeutics focusing on inhibiting cancer stemness pathways. Today, we continue to be at the forefront of this area of research and development with multiple compounds in phase 2/3 clinical trials and early pipeline. The U.S. Food and Drug Administration (FDA) granted three Orphan Drug designations for two of the company’s compounds: napabucasin, an orally-administered investigational agent hypothesized to inhibit cancer stemness pathways for the treatment of pancreatic cancer, and DSP-7888, an investigational cancer peptide vaccine, for the treatment of brain cancer and myelodysplastic syndrome (MDS).

Boston Biomedical was acquired by Sumitomo Dainippon Pharma of Osaka, Japan in April 2012. With greater resources and a global reach, we have expanded our R&D program, grown our portfolio of investigational compounds, and established a strong commercial operations infrastructure.

In 2017, industry veteran and former Chief Operating Officer Patricia S. Andrews was appointed to the role of Chief Executive Officer of Boston Biomedical. Ms. Andrews’ extensive experience and proven track record of operational success will be instrumental in driving the company forward into the next stage of growth and innovation through expanding its robust clinical pipeline, initiating additional clinical studies for its compounds across multiple tumor types, and setting the foundation for future commercialization of late-stage compounds.

In 2013, Boston Biomedical established its corporate headquarters in Cambridge, Massachusetts, aiming to continue to leverage our scientific excellence and leadership to advance the development of novel cancer therapeutics. We continue to expand our research capabilities and commercial operations at Boston Biomedical.

Our Timeline

  • 2017 - U.S. Food and Drug Administration grants Orphan Drug Designation for DSP-7888, an investigational cancer peptide vaccine, for the treatment of brain cancer and MDS
  • 2017 - Patricia S. Andrews appointed as Chief Executive Officer. Prior to this appointment, Ms. Andrews served as Chief Operating Officer of the company
  • 2016 - U.S. Food and Drug Administration grants Orphan Drug Designation for napabucasin, an orally-administered investigational agent hypothesized to inhibit cancer stemness pathways, for the treatment of pancreatic cancer and gastric/gastroesophageal junction cancer
  • 2013 - Boston Biomedical Headquarters and Sumitomo Dainippon Pharma Global Oncology Office open in Cambridge, MA
  • 2012 - Boston Biomedical acquired by Sumitomo Dainippon Pharma
  • 2011 - Boston Biomedical recognized as Oncology Pioneer (Alexandria Oncology Summit).
  • 2010 - Boston Biomedical selected as the sole healthcare industry recipient of the Frost & Sullivan 2010 North American Drug Discovery Technology Innovation of the Year Award.
  • 2009 - Boston Biomedical received a National Cancer Institute Cancer Stem Cells Initiative award in a nation-wide competition.
  • 2007 - Boston Biomedical begins independent operations
  • 2006 - Boston Biomedical is incorporated